- An important note In this issue of TreatmentUpdate we describe and detail important changes that have shifted scientific understanding about the effect of HIV ...
- Historically, decisions about when to start potent anti-HIV combination therapy (commonly called ART) have centred on different CD4+ cell count levels (or ...
- Researchers in 35 countries across all continents collaborated to recruit 4,685 HIV-positive adults who were in good health for START. Upon entry to the study, ...
- As opportunities for HIV testing and access to treatment continue to become more available, it is important that all people involved in these efforts remember ...
- The results of the START study have confirmed what some researchers have suspected for some time - the CD4+ cell count is an imperfect measure of the immune ...
- It is likely that immediate HIV treatment will become the standard of care in high-income countries when this viral infection is diagnosed in the future. It is ...
- In Canada and some other high-income countries, researchers estimate that a large proportion of HIV-positive people are not aware of their infection status. The ...
- The pharmaceutical company Gilead Sciences has been developing combinations of anti-hepatitis C virus (HCV) drugs. One combination consists of the following two ...
- Researchers at the University of Maryland and the U.S. National Institutes of Health (NIH) have found a relatively high rate of mental health conditions among ...
- People who share equipment for substance use are at increased risk for infection with germs, including hepatitis C virus (HCV) and HIV. In the past five years, ...
- Some direct acting antivirals (DAAs) used for the treatment of hepatitis C virus (HCV), including ledipasvir (in Harvoni), require an acidic environment in the ...
- Hepatitis C virus (HCV) infects the liver, causing inflammation. If left untreated, it also results in a gradual loss of healthy tissue and its replacement with ...